Pannexin-1 (PANX1) in Metabolic Diseases: Structural Basis, Molecular Mechanisms, and Pharmacological Significance
Cellular Signalling · 2027-02 · 150 · 112993
DOI: 10.1016/j.cellsig.2026.112993 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cellular Signalling, 2027-02. Verfasst von Guoqiang Fu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Jiangxi University of Chinese Medicine, No. 1688 Meiling Road, Nanchang 330004, PR China; National Engineering Research Center for Manufacturing Tech…. Die Arbeit nennt 129 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Metabolic diseases, including obesity, type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatotic liver disease (MASLD), atherosclerosis (AS), and diabetes-related complications, are characterized by disrupted glucose and lipid metabolism, chronic inflammation, oxidative stress, and progressive tissue dysfunction. Pannexin-1 (PANX1), a large-pore membrane channel that mediates regulated ATP release, has emerged as an important interface between metabolic stress and extracellular purinergic signaling. PANX1 influences metabolic homeostasis through ATP-dependent and broader signaling mechanisms that regulate insulin action and secretion, hepatic glucose and lipid metabolism, autophagy, vascular function, inflammatory responses, and regulated cell death. Its effects are highly context dependent. PANX1 can support metabolic homeostasis in adipocytes, pancreatic β cells, hepatocytes, and selected vascular cell populations, whereas sustained or dysregulated PANX1 signaling may promote inflammation, vascular dysfunction, ferroptosis, and pyroptosis under metabolic stress. These divergent actions are shaped by cellular origin, disease stage, and the local metabolic environment. This review summarizes current understanding of PANX1 structure, channel gating, and regulatory mechanisms and integrates predominantly preclinical evidence for its involvement in metabolic homeostasis and related diseases. We further examine the interactions of PANX1 with purinergic signaling, inflammation, oxidative stress, organelle homeostasis, and regulated cell death, together with current pharmacological strategies targeting PANX1. Although most available PANX1 modulators remain primarily mechanistic tools and lack direct evidence of therapeutic efficacy in metabolic disease models, these findings provide a foundation for the future development and evaluation of more selective PANX1-targeted interventions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Jiangxi University of Chinese Medicine, No. 1688 Meiling Road, Nanchang 330004, PR China; National Engineering Research Center for Manufacturing Technology of Solid Preparations of Traditional Chinese Medicine, Jiangxi…
- Jiangxi University of Chinese Medicine, No. 1688 Meiling Road, Nanchang 330004, PR China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Fu, G., Wang, Z., Rao, B., Liu, J., & Ouyang, H. (2027). Pannexin-1 (PANX1) in Metabolic Diseases: Structural Basis, Molecular Mechanisms, and Pharmacological Significance. Cellular Signalling, 150, 112993. https://doi.org/10.1016/j.cellsig.2026.112993
Vancouver
Fu G, Wang Z, Rao B, Liu J, Ouyang H. Pannexin-1 (PANX1) in Metabolic Diseases: Structural Basis, Molecular Mechanisms, and Pharmacological Significance. Cellular Signalling. 2027;150:112993. doi:10.1016/j.cellsig.2026.112993
BibTeX
@article{Fu2027,
author = {Fu, Guoqiang and Wang, Zhujun and Rao, Binfen and Liu, Jie and Ouyang, Hui},
title = {Pannexin-1 (PANX1) in Metabolic Diseases: Structural Basis, Molecular Mechanisms, and Pharmacological Significance},
journal = {Cellular Signalling},
year = {2027},
volume = {150},
pages = {112993},
doi = {10.1016/j.cellsig.2026.112993}
}
EUVIMED